Efficacy and tolerability of VCD chemotherapy in a UK real‐world dataset of elderly transplant‐ineligible newly diagnosed myeloma patients
| العنوان: | Efficacy and tolerability of VCD chemotherapy in a UK real‐world dataset of elderly transplant‐ineligible newly diagnosed myeloma patients |
|---|---|
| المؤلفون: | Lucia Chen, Catherine Prodger, Alexandros Rampotas, Charlotte Lees, Steve Prideaux, Nicola Gray, Fotios Panitsas, Sally Moore, Gavinda Sangha, Toby A. Eyre, Akhil Khera, Wen Yuen Lim, Ana Rita Gomes, Jaimal Kothari, Lauren Ellis, Ismini Tsagkaraki, Faouzi Djebbari, Karthik Ramasamy |
| المصدر: | European Journal of Haematology. 106:563-573 |
| بيانات النشر: | Wiley, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Cyclophosphamide, Clinical Decision-Making, Dexamethasone, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Statistical significance, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Humans, Adverse effect, Aged, Teniposide, Aged, 80 and over, Cumulative dose, business.industry, Disease Management, Retrospective cohort study, Hematology, General Medicine, Middle Aged, Prognosis, United Kingdom, Treatment Outcome, Tolerability, Health Care Surveys, 030220 oncology & carcinogenesis, Cohort, Female, Multiple Myeloma, business, 030215 immunology, medicine.drug |
| الوصف: | Objective There are limited data on the efficacy and tolerability of VCD chemotherapy in transplant-non-eligible (TNE) newly diagnosed myeloma (NDMM) patients. In this retrospective study, we set out to evaluate this triplet combination in this setting across Thames Valley Cancer Network (UK). Methods The primary end point was overall response rate (ORR). Secondary outcomes included event-free survival (EFS), overall survival (OS) and adverse events (AEs). Results In a total cohort of 158 patients, ORR for total cohort was 72.1%. Median EFS was 10.5 months, and for subgroups by age ( 600 mg: 7.8 vs ≤600 mg: 8.3 months, P = .665). Median OS was 46.9 months. The incidence rate of AE was as follows: any grade (76.8%), ≥G3 (27.1%), ≥G3 haematological AEs (7.9%), any grade infections (31.1%) and ≥G3 infections (11.9%). Conclusion This study demonstrated a good ORR achieved from fixed duration VCD, which was reasonably well tolerated. This was followed by modest median EFS. We envisage that the latter may be improved in this patient group with the use of a higher cumulative bortezomib dose (≥26 mg/m2 ) which showed a trend for improved EFS although without statistical significance (P = .13), and with the use of a higher cumulative cyclophosphamide doses (≥7000 mg, P = .02), subject to tolerability and close monitoring. |
| تدمد: | 1600-0609 0902-4441 |
| DOI: | 10.1111/ejh.13588 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::592ef3b4a573955c8651f021e3f11de9 https://doi.org/10.1111/ejh.13588 |
| Rights: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....592ef3b4a573955c8651f021e3f11de9 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16000609 09024441 |
|---|---|
| DOI: | 10.1111/ejh.13588 |